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Abstract
The resident microbiota in the human body, such as the oral cavity, gastrointestinal tract
and genitourinary tract, is able to provide resistance to disease. However, imbalances
in the microbial components can promote the growth of opportunistic microorgan‐
isms, such as yeasts of genus Candida. Fungal infections present as a major cause of
infectious diseases and the microorganisms of genus Candida are the most frequently
isolated pathogenic fungi in human fungal infections. Bacillus spp. and Lactobacillus spp.
are bacteria that have probiotic effects used in commercially available products and in
studies  that  aim  for  the  development  of  probiotics  able  to  inhibit  the  microbial
pathogenicity and restore the balance of resident microbiota. Thus, with increasing
fungus resistance to the use of antifungal agents, which are capable of causing serious
side effects to the host organism unable to destroy the target microorganism, it becomes
important to develop therapeutic and/or prophylactic alternatives that have a different
and an effective mechanism of action with capacity to combat fungal infections without
harming the patient. Probiotic bacteria provide an alternative strategy for the preven‐
tion and treatment of candidiasis and other infectious diseases.
Keywords: probiotic, Candida spp., Bacillus spp., Lactobacillus spp., prevention and
treatment
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1. Introduction
The incidence of fungal infections has increased significantly in the past 25 years [1]. Human
beings are colonized by a diverse and complex collection of microorganisms, contributing all
of them to host nutrition, development of the immune system, response to pathogens and
mucosal cell differentiation and proliferation [2].
Probiotic bacteria are also used in human and animal nutrition to influence beneficially the
balance of intestinal microbiota of the host. Probiotics have several beneficial effects related to
increasing digestion, strengthening the immune system and stimulating the production of
vitamin. The use of probiotics is aimed to reduce the use of antibiotics and improve animal
growth, as well as feed conversion [3].
Infectious diseases along with multidrug resistance are the major public health problem in
developing countries with increased mortality and morbidity [4, 5]. Apart from the threat of
multidrug resistance, several studies have confirmed that the continuous use of antibiotics can
damage human commensal microbiota [5, 6]. Thus, an alternative and effective research focus
is necessary to combat these pathogens with no effect on normal microbiota. In this regard,
the use of probiotics and their natural metabolic compounds can be a substitute in various
food and pharmaceutical industries [5].
There are around 600 pathogenic fungal species for humans and this group includes the fungi
that cause infection of skin (e.g., Malassezia species) and fungi that have the potential to cause
systemic infections (e.g., Cryptococcus neoformans and Candida albicans) [7]. The yeasts of the
genus Candida are the fourth most common cause of systemic infections acquired in hospi‐
tals in the United States with 50% mortality rates. The most pathogenic species is C. albicans
and can cause two major types of human infections: superficial infections, such as oral
candidiasis, and systemic infections [8, 9].
The genus Candida is commonly found in the oral cavity of healthy individuals, isolated from
approximately 75% of the population with a higher prevalence of C. albicans, followed by C.
tropicalis and C. glabrata [10]. Candida species are a frequent cause of recurrent infections in the
mucosa when favored by risk factors such as the use of antibiotics of broad spectrum and
corticosteroids for long time, human immunodeficiency virus (HIV) infection, radiotherapy
in the area of head and neck, the use of orthodontic appliances, deficient oral hygiene, among
other factors affecting immunocompromised patients that may result in transition of com‐
mensal phase of C. albicans to pathogenic [11, 12].
Under certain conditions of immunosuppression, such as individuals with acquired immu‐
nodeficiency syndrome (AIDS), oral manifestations are the most important and earliest
indicators of infection. The oral candidiasis is accepted internationally as a cardinal sign of
HIV infection and is present in 50% of patients with HIV infection and in 80% of patients with
AIDS [13, 14].
In Brazil during the period among 1996–2006, candidiasis was the second cause of deaths in
HIV-positive patients due to fungal infections, being responsible for an average of 39 annual
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deaths [15]. Moreover, oral candidiasis remains clinically relevant in these individuals, where
treatment is difficult and recurrent episodes are frequent, requiring multiple antifungal
treatments, which may lead to resistance selection [16, 17]. Due to this, C. albicans can develop
resistance to antifungals used to treat oral candidiasis, such as fluconazole and miconazole [18,
19].
Due to the high recurrence of Candida lesions, and the increased resistance of conventional
antifungal drugs in clinical practice, the continuous use of probiotics to prevent fungal
infections may be an interesting strategy. In this chapter, we discuss how probiotics can help
in the prevention and/or adjuvant treatment of candidiasis.
2. Probiotic
The history of probiotics began with the history of man; cheese and fermented milk were well
known to the Greeks and Romans who recommended their consumption, especially for
children and convalescents. The first association of probiotics and health benefits was made
at the turn of the century when the Russian scientist, Elie Metchnikoff, systematically studied
the composition of the microbiota and suggested that the ingestion of fermented milk would
improve this so-called autointoxication [20].
Probiotics play an important role in human health. There is general agreement on the important
role of the gastrointestinal microbiota in the health and well-being status of humans and
animals [21]. Probiotics are defined as live microorganisms, which when administered in
adequate amounts confer a health benefit on the host. This term is defined by a United Nations
and World Health Organization Expert Panel [22].
There was an increase in the number of searches, both in vivo and in vitro, related to the benefits
of probiotics on health and described in the literature for the treatment of infectious diseases
caused by fungi, viruses, and bacteria or diarrhea associated with the use of antibiotics,
alleviation of inflammatory chronic bowel disease, decreased risk of colon cancer, reduced
allergies, effect on intestinal microbiota [21], and anticancer therapies [23].
Other beneficial effects of probiotics include lowering serum cholesterol level [24–27],
improving lactose intolerance, increasing the utilization of nutrients, decreasing the use of
antibiotics [24, 27], and antidiabetic treatments [26, 28, 29]. In the context linking food and
health, probiotics have been the subject of numerous scientific studies and publications
demonstrating their therapeutic effectiveness on both systemic and gastrointestinal tract [21]
(Figure 1).
Microorganisms commonly used as probiotics belong to the heterogeneous group including
Bacillus, Lactobacillus, Bifidobacterium, Saccharomyces cerevisiae, and Escherichia coli [30, 31]
( Figure 1).
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Figure 1. Some properties of probiotics.
3. Lactobacillus spp.
3.1. General characteristics
Lactobacillus spp. are Gram-positive bacteria, facultative anaerobic bacilli found in the normal
microbiota of the gastrointestinal tract of birds and mammals, and genitourinary tract and oral
cavity in the humans [31, 32]. This genre is heterogeneous and the number of species is
constantly being modified due to the description of new species and reclassification of
others [33]. Some members of the genus Lactobacillus were reclassified into Carnobacterium [34],
Atopobium [35], Weissella [36], and Paralactobacillus [37]. In early 2007, 120 species composing
the genus Lactobacillus [33] and in 2008 over 145 new species have already been identified [38,
39].
Different Lactobacillus species found in the gastrointestinal tract are concerned with the balance
of microbiota and it has been widely studied due to their health-promoting properties [40].
Their effects on intestinal microbiota in terms of protection include competition for adhesion
sites with pathogenic microorganisms and antimicrobial substance production, such as
organic acids, lactic acid, carbon dioxide, and bacteriocins [41]. In addition, the regular use of
probiotic appears to prevent certain gastrointestinal disorders such as lactose intolerance [42].
In 1907, Elie Metchnikoff won the Nobel Medicine Prize because he noticed that the daily
consumption of Bulgarian yogurt (known for its rich composition in lactic acid bacteria) is
beneficial to health. Metchnikoff worked at the Pasteur Institute in Paris and he discovered L.
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bulgaricus and this strain was introduced into the commercial production of dairy products
across Europe. He dedicated the last decade of his life to the study of bacteria that produce
lactic acid as a means to increase human longevity. After the studies of Metchnikoff, the
concept of probiotics was established and a new microbiology area started to develop [43].
3.2. Lactobacillus as probiotics and its mechanism of action
The main characteristics that a Lactobacillus strain needs to have to exercise an effective
probiotic action against pathogenic microorganisms are related to three factors: the ability to
inhibit the adhesion and colonization of pathogenic microorganisms in the host tissues,
biosurfactant production, and hydrogen peroxide (H2O2). There is a collagen-binding protein
called 29 kD present on the surface of some lactobacilli, which causes it to be capable of binding
to collagen vaginal epithelial cells and to inhibit binding of pathogenic microorganisms to host
tissues in significant numbers [44]. Some strains of lactobacilli produce biosurfactants
generically known as surlactin, which are responsible for reducing the surface tension of liquid
and thereby inhibiting the adherence of microorganisms. Surlactin studies are very impor‐
tant to help in the understanding of the urogenital tract microbiota and their maintenance for
a balanced microbiota [45]. Other lactobacilli strains have the ability to produce hydrogen
peroxide, which can be toxic to microorganisms that do not produce catalase [46, 47].
According to Reid and Bruce [46], not all probiotic strains have the same mechanisms of action
and each has characteristics suitable for your application. For example, L. casei Shirota is
ingested daily for about 24 million people who do not have the 29-kDa protein and do not
produce H2O2. In the case of strain Shirota, its main action seems to be through the modula‐
tion of the host immune response.
In a recent study, Abedin-Do et al. [48] showed that some Lactobacillus strains exert innate and
adaptive immune responses via their binding to pattern recognition receptors expressed on
immune cells and many other tissues such as the intestinal epithelium. Furthermore,
Lactobacillus can modulate the expression of genes involved in the regulation of immune
system [49–53].
Members of our group evaluated the capacity of L. rhamnosus and its products to induce the
synthesis of cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-4, IL-6, IL-10, and
IL-12) by mouse macrophages. Jorjão et al. [54] used three microorganism preparations: live
L. rhamnosus (LLR) suspension, heat-killed L. rhamnosus (HKLR) suspension, and the super‐
natant of a heat-killed L. rhamnosus (SHKLR) suspension. LLR and HKLR groups were able to
significantly increase the production of TNF-α, IL-6, and IL-10. SHKLR also significantly
increased the production of TNF-α and IL-10 but not IL-6. All the L. rhamnosus suspensions
were not able to produce detectable levels of IL-1β or significant levels of IL-4 and IL-12. The
authors concluded that live and heat-killed L. rhamnosus suspensions are able to induce the
synthesis of different cytokines with pro-inflammatory (TNF-α and IL-6) or regulatory (IL-10)
functions, suggesting the role of strain L. rhamnosus ATCC 7469 in the modulation or in the
stimulation of immune responses.
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In order for probiotic strains to have a satisfactory action, they must remain alive against stress
challenges along the entire gastrointestinal tract, including the presence of bile in the small
intestine. Bile is highly toxic to microorganisms not adapted to intestinal conditions. Moreover,
some lactobacilli developed specific mechanisms to resist the deleterious effects caused by
these compounds [55]. Among these mechanisms, we can cite the efflux pump that actively
removes the acids and accumulated bile salts within the cytoplasm and the enzymatic activity
of hydrolases, which are capable of neutralizing deleterious effect of bile [56–58].
According to FAO WHO [22], the ideal characteristics of a probiotic strain of Lactobacillus
considered are as follows:
• Not pathogenic;
• Stable in acid and in the presence of bile;
• Adhesion ability in human mucosa;
• Colonize the intestine;
• Remain viable during storage and use;
• Have beneficial physiological effects and safe.
3.3. Lactobacillus in prevention and treatment of Candida infection
In vitro assays are important to evaluate the antifungal activity of each strain and characteri‐
zation of the mechanisms of action, performing as a screening to in vivo tests with experi‐
mental models.
Sookkhee et al. [59] isolated and identified different species of lactic acid bacteria from the oral
cavity of 130 volunteers in Thailand and they studied probiotic action against C. albicans in
vitro. The authors found 3790 different samples of lactic acid bacteria including the genera
Lactococcus, Lactobacillus, Streptococcus, Leuconostoc, and Pediococcus, and it was concluded that
L. paracasei and L. rhamnosus strains were two species that had the greatest number of clinical
isolates able to inhibit C. albicans.
Noverr and Huffnagle [60] examined the effect of living cultures, heat-killed cultures, and
supernatants of probiotic bacteria (L. casei, L. paracasei, and L. rhamnosus) on the morphogen‐
esis of C. albicans and observed an inhibition in the formation of germ tube when C. albicans
interacted with living cells or supernatant of Lactobacillus. It was also found that superna‐
tants obtained from cultures of 2 h inhibited germ tube formation of C. albicans. However, the
addition of 24-h growth cultures took complete inhibition, suggesting that the accumulation
of a soluble compound of the supernatant is responsible for this inhibition.
Coman et al. [61] evaluated the antifungal activities of two probiotic strains, L. rhamnosus
IMC 501® and L. paracasei IMC 502®, and their 1:1 combination, named SYNBIO®, using agar
well-diffusion method and liquid coculture assay. They tested probiotic strains in eight strains
of Candida, including C. albicans, C. krusei, C. glabrata, C. parapsilosis, and C. tropicalis. All the
Candida strains are strongly inhibited, except C. glabrata and C. tropicalis, and during the
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coculture assay, the inhibitory activity of probiotic bacteria against Candida strains was
approximately 40% in some cases and absent in other cases, in particular against some strains
of C. albicans and C. tropicalis. The authors concluded that in vitro screening of Lactobacillus
strains according to their activity in various environmental conditions might be a valuable
method that could precede clinical efficacy studies for adjunct treatment with probiotics in
cure of different infections.
Parolin et al. [62] identified 17 clinical strains of Lactobacillus from the vaginal cavity of healthy
premenopausal women, including the following species: L. crispatus, L. gasseri, and L. vaginalis,
and evaluated their in vitro activity against Candida spp. (nine strains) and characterized their
antifungal mechanisms of action. In general, the strains tested were more active toward C.
albicans. No Lactobacillus strains showed activity against C. krusei and C. parapsilosis. All strains
produced hydrogen peroxide and lactate, and in particular, L. crispatus BC2, L. gasseri BC10,
and L. gasseri BC11 appeared to be the most active strains in reducing pathogen adhesion. It
was concluded that these in vitro assays are prerequisites for the development of new
therapeutic agents based on probiotics for prophylaxis and adjuvant therapy of Candida
infection.
Some in vivo studies also show the effectiveness of probiotics in Candida infection. Wagner et
al. [63] demonstrated that the inoculation of probiotics (L. acidophilus, L. reuteri, L. casei GG,
and B. animalis) in immunodeficient mice reduced the density of C. albicans in gastrointesti‐
nal tract, incidence of systemic candidiasis, and prolonged the survival of adult and neona‐
tal mice. Probiotic bacteria also modulated antibody and cell-mediated immune responses to
C. albicans. The authors demonstrated that probiotic bacteria can protect immunodeficient mice
from candidiasis; however, none of the probiotic bacteria we studied completely eliminated
C. albicans from the alimentary tract.
Matsubara et al. [64] evaluated the oral colonization by C. albicans in experimental murine
immunosuppressed and treatment with L. acidophilus and L. rhamnosus. The colonization by
C. albicans on the oral mucosa, started on day 1 after inoculation, remained highest from day
3 until day 7 and then decreased significantly. Probiotic bacteria reduced Candida coloniza‐
tion on the oral mucosa significantly compared to the untreated group of animals (negative-
control group). The reduction of yeast colonization in the group treated with L. rhamnosus was
significantly higher compared to the group receiving nystatin (positive-control group). The
authors concluded that the treatment with probiotics in this model may be an effective
alternative to prevent it.
Deng et al. [65] evaluated the probiotic action in vitro and the anticolonization capacity of L.
paracasei FJ861111.1 in vivo in mice infected with other selected pathogenic microorganisms.
In vitro results showed that Shigella dysenteriae, Staphylococcus aureus, Cronobacter sakazakii, E.
coli, and C. albicans were inhibited by L. paracasei FJ861111.1 that presented elevated survival
at pH 2.5 and bile salt concentration at 0.3%. In vivo results demonstrated that the ferment‐
ed milk with L. paracasei improved significantly the total population of bacteria, and the
presence of Lactobacillus in the feces of mice. The colonization by C. albicans was significantly
inhibited in the intestine of mice after infection and demonstrated the potential of this strain
used as a probiotic organism for the production of functional fermented milk.
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Although mice and rats are the gold standard for Candida studies, economic and ethical issues
limit the use of mammals in these experiments, especially when a large number of strains need
to be analyzed [66]. Invertebrate models have been used to study the microbial pathogenici‐
ty and pathogen-host interactions, which provided considerable insight into different aspects
of microbial infection [67]. In this respect, Galleria mellonella has been found to be an interest‐
ing invertebrate model for the study of the pathogenicity of C. albicans [68–71]. Recently, our
laboratory developed pioneering in vivo study to evaluate the probiotic action of L. acidophi‐
lus in the experimental candidiasis in G. mellonella. Vilela et al. [31] demonstrated that the
inoculation of L. acidophilus into G. mellonella infected with C. albicans reduced the number of
yeast cells in the larval hemolymph and increased the survival of these animals. However, L.
acidophilus exerted no inhibitory effect on C. albicans filamentation in G. mellonella tissues. In
this study, we verified that G. mellonella is an adequate model for the study of the probiotics.
4. Bacillus spp.
Bacillus spp. were classified a long time as only soil microorganisms, but they are also
commensal microorganisms of the gut of humans and animals due to the great adaptability to
the intestinal environment, representing part of your natural life cycle [72–74]. Some Bacillus
species have been used as probiotics for at least 50 years, but scientific interest for these
microorganisms has occurred mainly in the last 15 years [30, 75].
Among the large number of probiotic products in use today are bacterial spore formers, mostly
of the genus Bacillus. Bacillus bacteria have been used widely as putative probiotics because
they secrete many exoenzymes [76–78]. The species that have been most extensively exam‐
ined include B. subtilis, B. clausii, B. coagulans, B. licheniformis, and B. polyfermenticus [26, 30, 79].
Although it requires an evaluation in each case, many species of Bacillus are considered as
nonpathogenic and safe for animal and human consumption [79–81].
Used primarily in their spore form, these products have been shown to prevent gastrointesti‐
nal disorders and the diversity of species used and their applications are astonishing [30], then,
demonstrating that exert immune stimulation, antimicrobial activity, and competitive
exclusion. Studies have shown that these bacteria are able to grow inside the intestinal tract
and could be considered temporary residents. This is important because it indicates that they
are not exogenous microorganisms but may have unique symbiotic relationship with the
host [74].
4.1. General characteristics
The members of genus Bacillus are Gram-positive, aerobic or facultative anaerobic, catalase-
positive, and spore-forming bacteria [82, 83]. These microorganisms are saprophytic com‐
mon in soil, water, dust, and air [84] and also involved in food spoilage [85]. These bacteria
are considered allochthonous and enter the gut by association with food [30] or in an endo‐
symbiotic relationship with their host, being able to survive temporarily and proliferate within
the gastrointestinal tract [30, 86].
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B. subtilis is a model microorganism for studies involving the genus Bacillus [87]. This species
is a widely used oral vaccine delivery system since it has been classified as a novel food
probiotic for both human and animal consumption [88, 89]. The beneficial effects of B. subtilis
on the balance of the gastrointestinal microbiota justify its use as probiotic in pharmaceutical
preparations, for the prevention and treatment of intestinal disorders and the reduction of
inflammation [90–92].
4.2. Spores as probiotics
Sporulation of Bacillus spp. represents a protection process, which is usually induced by low
levels of nutrients and conditions unfavorable to the survival of the bacteria in vegetative
form [93]. The spores are extremely resistant cell structures that when exposed to appropri‐
ate abiotic factors, through the germination, they can return to vegetative form [94].
Bacterial spore formers are being used as probiotic supplements for use in animal feeds, for
human dietary supplements, as well as in registered medicines [74]. The use of spore-based
products raises a number of questions. Since the bacterial species being used are not consid‐
ered resident members of the gastrointestinal microbiota, how do they exert a beneficial effect?
According to Cutting [74], while often considered soil organisms this conception is mis‐
placed and Bacilli should be considered as gut commensals. Therefore, in fact, the question to
be answered is what produces the probiotic effect: the vegetative cells (spores germinated) or
the spores themselves? The natural life cycle of spore-forming microorganisms involves spore
germination, sporulation, and re-proliferation when nutrients are scarce [30]. According to
these authors, although it is unlikely that they are true commensals, a unique dual life cycle
of spore formers in the environment and within the gut of animals could represent a mecha‐
nism that may be responsible for probiotic action.
Bacillus spp. forms thermostable spores and shows advantages over other microorganisms
non-spore-forming, but also have probiotic activity. Thus, the product can be stored at room
temperature in the dried form without any deleterious effect on the viability. Furthermore,
since spores are extremely stable and resistant, they are able to survive low pH of gastric
barrier [95, 96]. Therefore, a particular dose of ingested spores can be stored indefinitely
without refrigeration and the desired dose of vegetative bacteria will reach the small intes‐
tine intact [74].
The research efforts and the search for new perspectives for clinical and nutritional applica‐
tions with probiotic preparations that last comparatively more than other pharmaceutical
drugs are justified because the spores are more resistant than the vegetative cells. This allows
for greater reliability in the treatment method with probiotics and reduces the cost of produc‐
tion [79].
4.3. Mechanism of action of Bacillus probiotic
Before a bacterial strain can be considered probiotic, some criteria must be assessed as
inhibition capacity in the growth of harmful microorganisms, not toxic, not pathogenic, and
be tolerant to acid, bile salt conditions, and pancreatic secretions in order to reach the small
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and large intestines, its ability to adhere to intestinal epithelial cells [82, 97–99], remain viable
during transport and storage, exert beneficial effects on the host, stabilize the intestinal
microbiota, adhere to the intestinal epithelial cell lining, and produce antimicrobial substan‐
ces toward pathogen [82, 98].
Many authors have proposed that the properties of adhesion are a decisive factor for the
selection of new probiotic strains. The mechanisms of action of probiotics against gastrointes‐
tinal pathogens consist principally on the following:
• Competition for nutrients and sites of accession;
• Production of antimicrobial metabolites [21, 100];
• Changes in environmental conditions;
• Modulation of the immune response of the host [21, 101].
The principal mechanism by probiotics is the production of antimicrobials that inhibit
pathogenic microorganisms. Bacillus species produce a large number of antimicrobials and
include bacteriocins and bacteriocin-like inhibitory substances, subtilin and coagulin, as well
as antibiotics, surfactin, iturins A, C, D, E, and bacilysin [30, 102]. In 1979, Ozawa et al. [103]
demonstrated that B. subtilis var. natto inhibited the growth of C. albicans in the intestinal tract
and [104] showed that a surfactin had activity against yeast.
Figure 2. Mechanism of action of Bacillus probiotic.
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Stimulation of the immune system or immunomodulation is considered an important
mechanism to probiotics. Studies in humans and animal models have provided that the oral
administration of spores stimulates the immune system, and this confirms that spores are
neither innocuous gut passengers nor treated as a food. Helper lymphocyte (Th1) responses
are important for IgG synthesis but more importantly for cytotoxic T-lymphocyte recruit‐
ment, and for the destruction of intracellular microorganisms, and involve presentation of
antigens on the surface of the host cell by a class I major histocompatibility complex (MHC)-
processing pathway [30].
Studies have shown that small amount of inoculum of B. subtilis spores can germinate in the
small intestine, grow, proliferate, and then again sporulate [105, 106]. Thus, the spores of
Bacillus spp. can germinate in significant numbers in the jejunum and ileum [107], and
stimulate and regulate the synthesis of immunoglobulin A, the pro-inflammatory cytokines
such as tumor necrosis factor and interferon γ, and the helper T lymphocytes [108]. There‐
fore, through colonization, immune stimulation, and antimicrobial activity developed by these
bacteria it is possible to prove that they have the potential probiotic effect [109].
Different mechanisms have been proposed for competitive exclusion agents including
competition for host-mucosal receptor sites, secretion of antimicrobials, production of
fermentation by-products, such as volatile fatty acids, competition for essential nutrients, and
stimulation of host immune functions [30] (Figure 2).
4.4. Studies with Bacillus spp. as probiotics
In literature, there are in vivo and in vitro studies of Bacillus spp. about the benefits of their
probiotic action in humans and animals. However, despite its recognized probiotic action and
its benefits to human and animal health, to date, there are no studies on the effect of Bacillus
spp. in the genus Candida. Subsequent text describes some studies with the genus Bacillus as
probiotic.
Lee et al. [26] studied the potential probiotic characteristics of B. polyfermenticus KU3 isolated
from kimchi, a Korean dish made from fermented vegetables. The spore cell of B. polyfermen‐
ticus KU3 was highly resistant to artificial gastric juice and survived for 24 h in artificial bile
acid. B. polyfermenticus KU3 did not generate the carcinogenic enzymes, β-glucosidase, N-
acetyl-β-glucosaminidase, and β-glucuronidase, and adhered strongly to HT-29 human
intestinal epithelial cell lines. The authors found that B. polyfermenticus KU3 strongly inhibit‐
ed the proliferation of cancer cells such as HeLa, LoVo, HT-29, AGS, and MCF-7 cells. The
supernatant of B. polyfermenticus KU3 had an anticancer effect against HeLa and LoVo cells.
Conversely, the proliferation of normal MRC-5 cells was not inhibited. They also demonstrat‐
ed the anti-inflammatory activity of B. polyfermenticus KU3 under inflammatory conditions, as
shown by the reduction in nitric oxide and pro-inflammatory cytokines (TNF-α, IL-10, TGF-
β2, and COX-2). This study demonstrated the probiotic characteristics of B. polyfermenticus KU3
and provided evidence for the effect of this bacterium against various cancer cells.
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Studies performed by Thirabunyanon and Thongwittaya [99] investigated the activity of
isolates of Bacillus spp. for possible use as potential probiotics, and their protective inhibi‐
tion activity against Salmonella enteritidis infection. The gastrointestinal tracts of native chickens
were evaluated for use as a potential probiotic. Bacillus demonstrated higher growth inhibi‐
tion of seven food-borne pathogens, including S. enteritidis, S. typhimurium, E. coli, B. cereus, S.
aureus, Listeria monocytogenes, and Vibrio cholerae. The authors concluded that B. subtilis NC11
has a protective activity against S. enteritidis infection, and is able to competitively exclude it
from its original site in the gastrointestinal tract, which is the beginning of the route of food-
pathogenic contamination.
Rhee et al. [110] studied the effect of bacteria administered orally on the development of the
gut-associated lymphoid tissue (GALT) in infant rabbits and B. subtilis showed greater
importance in GALT development. Besides, B. subtilis secretes antimicrobial agents, as
coagulin, amicoumacin, and subtilisin, which may have probiotic effect by suppressing the
growth of competing microorganisms, such as enteric pathogens.
Pinchuk and colleagues [90] demonstrated that a probiotic strain B. subtilis 3, originally isolated
from animal feed, has inhibitory effect against Helicobacter pylori due to the production of
antibiotics, including amicoumacin A. The group of isocoumarin antibiotics (which the
amicoumacin A belongs) can exert, among other properties, anti-inflammatory and anti-tumor
actions, and present potential for use in the treatment of H. pylori infection.
In the human and animal consumption, the spores of B. subtilis were used as probiotics and
competitive exclusion agents [107, 111], and, in some countries, B. subtilis was applied in oral
bacteriotherapy of gastrointestinal disorders [107].
Bacillus probiotics were developed for topical and oral treatment of uremia [30]. B. coagulans
had the ability to secrete a bacteriocin, coagulin, that has activity against a broad spectrum of
enteric microbes [112] and since 1983 [113] showed the beneficial effects of Bacillus probiot‐
ics on urinary tract infections.
Ghelardi and colleagues [114] aimed to investigate the survival and persistence of B. clausii in
the human gastrointestinal tract following oral administration as spore-based probiotic
formulation. The authors concluded that B. clausii strains can have different ability to sur‐
vive in the intestinal environment. B. clausii spores administered as a liquid suspension or a
lyophilized form behave similarly in vivo and B. clausii spores survive transit through the
human gastrointestinal tract, and they can germinate, outgrowth, and multiply as vegetative
forms.
The use of Bacillus species as probiotic is expanding rapidly with increasing number of studies
demonstrating immune stimulation, antimicrobial activities, and competitive exclusion by
these microorganisms. Most research with Bacillus has been performed in animals and some
clinical studies also in humans. Thus, the question is: Are the findings relevant to probiotic
research in humans?
Therefore, if the results are promising and not only the bacteria are becoming superbacteria,
but also other microorganisms such as fungi, why not apply the probiotic properties of Bacillus
spp. in the genus Candida?
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5. Conclusion and future perspective
This chapter sought to provide the reader knowledge about the probiotic action of bacteria
Bacillus spp. and Lactobacillus spp., describing the characteristics of microorganisms, the
probiotic mechanism of action, and the studies described in the literature.
The high prevalence of Candida spp. associated with the increased resistance of microorgan‐
isms to conventional antifungal treatments boosts the development of research for new
treatments to infections caused by Candida, such as probiotics. The treatment with probiotics
promotes the reestablishment of the natural condition of microbiota with advantages over
conventional antifungal because they do not induce microbial resistance, are nontoxic when
administered in adequate amount, and therefore do not produce undesirable side effects, and
also stimulate the immune system.
Infectious diseases along with the resistance of microorganisms to drugs represent serious
problem in health. The knowledge of microorganisms that have characteristics capable of
influencing the pathogenicity of Candida, and that characterize possible methods of preven‐
tion and treatment for candidiasis, is important, mainly, to provide alternative for microbial
resistance without causing harmful side effects to the human organism and do not cause
resistance to the fungus.
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